Swiss National Bank Lowers Stock Position in Indivior PLC $INDV

Swiss National Bank lessened its holdings in Indivior PLC (NASDAQ:INDV) by 10.9% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 193,173 shares of the company’s stock after selling 23,622 shares during the quarter. Swiss National Bank owned 0.14% of Indivior worth $1,812,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently added to or reduced their stakes in INDV. Stifel Financial Corp boosted its holdings in Indivior by 24.0% in the 4th quarter. Stifel Financial Corp now owns 12,675 shares of the company’s stock valued at $158,000 after purchasing an additional 2,450 shares in the last quarter. Boothbay Fund Management LLC boosted its stake in shares of Indivior by 65.5% during the 4th quarter. Boothbay Fund Management LLC now owns 458,874 shares of the company’s stock worth $5,879,000 after acquiring an additional 181,637 shares in the last quarter. Melqart Asset Management UK Ltd boosted its stake in shares of Indivior by 675.6% during the 4th quarter. Melqart Asset Management UK Ltd now owns 104,790 shares of the company’s stock worth $1,303,000 after acquiring an additional 91,280 shares in the last quarter. Tudor Investment Corp ET AL boosted its stake in shares of Indivior by 113.1% during the 4th quarter. Tudor Investment Corp ET AL now owns 45,478 shares of the company’s stock worth $565,000 after acquiring an additional 24,137 shares in the last quarter. Finally, Schonfeld Strategic Advisors LLC purchased a new stake in shares of Indivior during the 4th quarter worth approximately $1,686,000. Hedge funds and other institutional investors own 60.33% of the company’s stock.

Indivior Stock Up 1.1%

INDV stock opened at $24.32 on Friday. Indivior PLC has a 1 year low of $7.33 and a 1 year high of $24.64. The stock’s 50 day moving average price is $17.81 and its 200 day moving average price is $13.04.

Indivior (NASDAQ:INDV) last posted its earnings results on Thursday, July 31st. The company reported $0.51 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.26 by $0.25. Indivior had a negative return on equity of 86.28% and a net margin of 6.65%.The firm had revenue of $302.00 million for the quarter, compared to analyst estimates of $239.43 million. Indivior has set its FY 2025 guidance at EPS. On average, research analysts expect that Indivior PLC will post 1.22 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on the company. Craig Hallum boosted their price target on Indivior from $15.00 to $22.00 and gave the stock a “buy” rating in a research note on Monday, June 30th. HC Wainwright assumed coverage on Indivior in a research note on Wednesday, August 6th. They set a “buy” rating and a $27.00 price target on the stock. Wall Street Zen raised Indivior from a “buy” rating to a “strong-buy” rating in a research note on Saturday, June 21st. Finally, Jefferies Financial Group assumed coverage on Indivior in a research note on Tuesday, July 22nd. They set a “buy” rating and a $20.00 price target on the stock. One equities research analyst has rated the stock with a Strong Buy rating and five have given a Buy rating to the company’s stock. Based on data from MarketBeat.com, Indivior presently has a consensus rating of “Buy” and an average price target of $19.60.

Indivior Company Profile

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.